German Center for Infection Research: Start-Up EBViously Founded
December 18, 2024
December 18, 2024
BRAUNSCHWEIG, Germany, Dec. 18 (TNSres) -- The German Center for Infection Research issued the following news release:
EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious diseases such as infectious mononucleosis, secondary diseases such as multiple sclerosis and myalgic encephalomyeliti . . .
EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious diseases such as infectious mononucleosis, secondary diseases such as multiple sclerosis and myalgic encephalomyeliti . . .